Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

NTK accuses Daiichi Sankyo of misleading statements, causing damage in Fortis Healthcare open offer. JPY 200 billion damages ...

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody drug conjugate (ADC) patritumab deruxtecan, intended for ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

IHH Healthcare's Singapore-headquartered indirect subsidiary Northern TK Venture Pte Ltd (NTK) on Thursday accused Daiichi Sankyo of ''misleading statements'' concerning the ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Progress in Lung Cancer Across Daiichi Sankyo’s DXd ADC Portfolio Updated DATROWAY® (datopotamab deruxtecan) combination data across three early-phase trials will be highlighted in patients ...